Latest news with #cancertherapy
Medscape
15 hours ago
- Health
- Medscape
Targeted but Toxic? Addressing the Safety Challenges of ADCs
Antibody-drug conjugates (ADCs) are an evolving class of targeted cancer therapy that combines a monoclonal antibody with a cytotoxic payload or agent via chemical linkers. Attaching the monoclonal antibody with the cytotoxic agent enables an ADC to target cancer cells, maximizing efficacy and minimizing off-target toxicity. Several ADCs, including HER2+, HR+, and triple-negative breast cancer (TNBC) subtypes have shown significant efficacy in treating breast cancer. The ADCs currently approved by the FDA for the treatment of metastatic breast cancer and as an adjuvant treatment for HER2+ breast cancer include trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), patritumab-DXd, and sacituzumab govitecan (SG). Although ADCs have demonstrated significant efficacy, treatment-related toxicity, mainly from off-target effects of cytotoxic payloads and unintended bystander damage, remains a concern. A recent systemic review and meta-analysis by Zhu et al on ADCs found treatment-related adverse events of 91.2% for all-grade adverse events and 46.1% for grade ≥ 3 adverse events. Lymphopenia (53%) was the most common all ‐ grade adverse event, and neutropenia (31.2%) was the most common grade ≥ 3 adverse event. Approximately 13.2% of patients discontinued ADC treatment due to serious toxic events. This article discusses some of the common hematologic, cardiac, and gastrointestinal (GI) toxicities/adverse events associated with ADCs and their management. Managing Hematologic Adverse Events Neutropenia, anemia, and thrombocytopenia are common hematologic toxicities associated with ADCs. The most common cytopenia associated with T-DXd is neutropenia. In the DESTINY-Breast03 trial, any-grade neutropenia was observed in 42.8% of patients taking T-DXd. Although grade 3 or higher neutropenia was reported in 19.1% of patients, the DESTINY-Breast01 trial reported only 1.6% of patients experienced febrile neutropenia associated with T-DXd. The incidence of all-grade neutropenia associated with T-DM1 across trials ranges from 5% to 11% with grade ≥ 3 neutropenia, including febrile neutropenia, occurring in up to 6% of patients. Neutropenia-associated with ADC toxicity can be managed through dose modifications and temporary treatment holds. Prophylactic granulocyte colony-stimulating factor can decrease the incidence, duration, and severity of neutropenia and is indicated for patients with a history of neutropenic complications. Since the risk of developing febrile neutropenia with T-DXd is low (≤ 10%), prophylactic granulocyte colony-stimulating factor is typically not indicated. Regarding anemia, the EMILIA and TH3RESA trials reported the incidence of anemia associated with T-DM1 to be only 2.7%. However, findings from a randomized open-label phase 3 trial found grade 3 or higher anemia in 8.1% of patients receiving T-DXd. A phase 1/2 multicenter open-label study reported anemia in 18.7% of patients receiving patritumab-DXd, a HER3-directed ADC. A common approach to managing grades 3 and 4 anemia associated with ADCs involves withholding the treatment until anemia is lower than grade 2. The WSG-ADAPT, TH3RESA, and EMILIA trials found all-grade thrombocytopenia occurs in up to 28% of patients receiving T-DM1. The EMILIA trial reported severe thrombocytopenia in up to 12% of patients treated with T-DM1; the DESTINY-Breast03 trial reported grades 3 and 4 thrombocytopenia in 7% of patients receiving T-DXd; and a phase 2 study reported grades 3 or higher thrombocytopenia in 1.7% of patients receiving HER3-DXd. Managing thrombocytopenia involves reducing the dose of the ADC until patients recovery to grade 1 is achieved and continuing with the reduced dosage for the duration of treatment. Managing Cardiotoxicity Cardiotoxicity is a known adverse event of HER2-targeted therapies such as T-DM1 and T-DXd. HER2 receptors are usually expressed on cardiomyocytes and play a key role in normal fetal heart development and the growth and survival of adult cardiomyocytes. Preclinical studies suggest T-DM1 can exert more cardiotoxic effects than trastuzumab, though clinical evidence remains low. A pooled meta-analysis by Pondé et al of data from 1961 patients exposed to T-DM1 in seven trials found 3.37% experienced at least one cardiac event. Most of the events (2.04%) were grade 1 or 2 left ventricular ejection fraction (LVEF); grade 4 LVEF events were rare. Although no specific guidelines exist for the management of T-DM1-associated cardiotoxicity, general recommendations for ADC treatment from the 2022 European Society of Cardiology Cardio-Oncology guidelines suggest a baseline ECG prior to treatment initiation and then echocardiography every 3 months thereafter, along with natriuretic peptide monitoring throughout treatment. Treatment interruption and reassessment are indicated for patients whose LVEF drops to ≥ 10% from pretreatment value or to < 40%. For T-DXd, cardiac events were minimal in DESTINY-Breast01 and Breast03 trials, with few patients experiencing reversible LVEF reductions; no events of heart failure were reported. However, the DESTINY-Breast04 trial showed that 11.9% of patients receiving T-DXd who had not been previously treated with an anti-HER2 agent had LVEF reductions of 10%-19%, and 1.5% had > 20%. Management of ADC-related cardiac events includes reducing or permanently withdrawing treatment. Following treatment interruption, ADCs may be resumed with increased monitoring if cardiac function recovers. Permanent discontinuation may be required for patients whose LVEF remains significantly low or who develop heart failure. Managing Gastrointestinal Toxicity Nausea and vomiting are two of the most common GI toxicities associated with T-DXd treatment. In the DESTINY-Breast03 trial, 72.8% (187 of 257) and 6.6% (17 of 257) of patients had any grade and grade ≥ 3 nausea, respectively, post-T-DXd treatment. Vomiting was also commonly reported, with 44.0% (113 of 257) and 1.6% (4 of 257) of patients experiencing any grade and grade ≥ 3 vomiting, respectively. Based on these findings and other clinical trial data, the National Comprehensive Cancer Network Clinical Practice in Oncology guidelines reclassified T-DXd as highly emetogenic. The emetogenic classification of SG varies by guideline but is generally categorized as high-moderate or high. According to pooled analysis data by Pedersini et al, 65.6% and 43.7% of patients experienced nausea and vomiting, respectively, with SG therapy. Most cases of nausea and vomiting were grade 1 or 2, and approximately 10% were grade 3 or 4. T-DM1 is categorized as a low emetogenic since its associated toxicities are easier to manage. Prophylactic antiemetic therapy for nausea and vomiting associated with ADCs varies based on guidelines and emetogenic categorization. Due to their higher emetogenic risk, a 3- or 4-drug antiemetic regimen (eg, 5-hydroxytryptamine 3 receptor antagonist, dexamethasone, neurokinin-1 receptor antagonist, olanzapine) is recommended for T-DXd and SG. Due to its low emetic risk, prophylactic antiemetics are not usually recommended for T-DM1 but may be considered based on a patient's individual risk factors. In general, dose interruption or modification is recommended for patients on T-DXd or SG who experience grades 3 or 4 nausea and vomiting until they recover to grade 1 toxicity. Treatment with SG may be permanently stopped if grade 3 or 4 toxicity lasts for more than 3 weeks. Diarrhea is another common GI adverse event associated with ADC use and is reported to occur in 59.7% of patients treated with SG, 30.2% with T-DXd, and 17.5% with T-DM1. Management for ADC-associated diarrhea includes loperamide, intravenous fluids, metoclopramide with or without dexamethasone, and olanzapine for refractory cases. Preventive strategies include dietary modifications (eg, high fiber diet), oral supplements and probiotics, and nutritional counseling. Managing Interstitial Lung Disease Interstitial lung disease (ILD) is a group of lung disorders characterized by fibrosis or scarring of the lungs. Risk factors for the development of drug-induced ILD include increased age (≥ 60 years), smoking, pre-existing lung conditions, higher alcohol consumption, and renal failure. A pooled analysis of eight T-DXd monotherapy studies suggested 15.8% of the population developed ILD/pneumonitis with 77.7% experiencing grade 1 or 2 events. The DESTINY-Breast03 trial showed the incidence of drug-related ILD/pneumonitis with T-DXd to be lower at 10.5%. In phase 3 of the ASCENT trial, ILD associated with SG or T-DM1 was rare in patients with metastatic TNBC. In addition, the phase 1/2 study, U31402-A-J101, investigating HER3-DXd reported ILD in 6.6% of patients; most cases were grade 1 or 2, three were grade 3, and one was grade 5. Regular monitoring and assessment of patients are important to prevent ILD/pneumonitis. Per the current T-DXd ILD/pneumonitis guidelines, a computed tomography scan should be obtained prior to initiating ADC treatment and every 9-12 weeks thereafter during treatment. Patients who develop ILD/pneumonitis should undergo CT scans every 1-2 weeks (or as clinically indicated). In cases of suspected ILD/pneumonitis, consultation with a pulmonary specialist is recommended. Treatment for ILD/pneumonitis includes initiation of corticosteroid therapy immediately upon detection of grade ≥ 2 ILD/pneumonitis; corticosteroid treatment may be considered in patients with grade 1 ILD/pneumonitis. Guidelines for treating ILD/pneumonitis include starting corticosteroids immediately after detecting grade ≥ 2 ILD/pneumonitis and considering corticosteroid treatment in case of grade 1 cases. Future Directions Regular monitoring and prophylactic management are essential to reduce and mitigate ADC-related toxicities and maximize treatment benefits. Other toxicities associated with ADCs include neurological, embryo-fetal, ocular, and dermatological events. Continued research is needed to understand the mechanisms that contribute to ADC-related toxicities and provide additional management approaches to reduce risk. In addition, future research efforts should focus on the development of highly targeted therapeutics aimed at specific antigens, the creation of safer drug payloads, and the innovation of new linker technologies to reduce off-target effects. Novel ADCs are in development to enhance cancer immunotherapy by targeting immune cells or components of tumor microenvironment rather than tumor-associated antigens directly. These include immunostimulatory antibody conjugates that use immune-activating payloads (eg, Toll-like receptors 7 and 8, stimulators of interferon genes agonists) instead of traditional cytotoxins. Early clinical trials have evaluated immunostimulatory antibody conjugates against targets like HER2 and carcinoembryonic antigen. In addition, other ADCs are being developed to target elements of the tumor microenvironment such as T cells and fibroblasts. These novel approaches are likely to produce unique toxicity profiles, highlighting the need for a deeper understanding of their safety as development progresses.
Yahoo
15-07-2025
- Business
- Yahoo
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer DALLAS, July 15, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy. In a peer-reviewed study published in Frontiers in Oncology, Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module.1 Transforming Cancer Combination Therapy Development The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer (TNBC). "This AI-powered module is a transformative step in our mission to deliver personalized cancer treatments," said Panna Sharma, CEO & President of Lantern Pharma. "By leveraging our RADR® platform to analyze complex multi-omics and clinical trial data, we identified optimal DDA-DDRi combinations that guided the development of our TNBC trial. We believe this approach could reduce combination therapy development timelines and costs by one-third compared to traditional methods." The module integrates genomic, transcriptomic, and clinical data to predict synergistic drug interactions, optimize therapeutic outcomes, and identify biomarker-defined patient subpopulations likely to respond to specific combinations. This data-driven approach directly informed the design of Lantern's FDA-cleared Phase 1B/2 trial in TNBC for LP-184 and olaparib, with potential to improve response rates and reduce toxicity. Key insights from the study powering the AI module include: Non-PARP Inhibitor Promise: Non-PARP DDRi combinations, particularly WEE1 inhibitors like adavosertib with platinum agents, showed an 80% positive outcome rate in interstrand cross-linker trials, with strong efficacy in TP53-mutated cancers, directly informing future trial design. Biomarker-Driven Success: Biomarkers such as TP53 mutations and HRD signatures were critical predictors of response, enabling patient stratification to maximize efficacy. Toxicity Mitigation: The use of novel formulations like liposomal doxorubicin in combination regimens reduced cardiotoxicity, providing a safer backbone for combination strategies. Emerging Trends: The analysis emphasizes the patterns in treatment effectiveness, safety, and emerging trends across various cancer types and discusses the potential of biomarkers to guide treatment selection and improve patient outcomes. The module's multi-agentic framework integrates specialized AI agents for data aggregation, drug classification, predictive modeling, biomarker identification, and optimization, creating a dynamic system that is planned to evolve along with new data. The system's continuous learning capability ensures adaptability, enabling Lantern to refine regimens and accelerate future trials across diverse cancer indications. The company is exploring licensing and commercialization opportunities to expand the application of this technology, further revolutionizing combination therapy development. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes. Please find more information at: Website: LinkedIn: X: @lanternpharma Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. 1 Fontenot R, Biyani N, Bhatia K, Ewesuedo R, Chamberlain M and Sharma P (2025) Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. Front. Oncol. 15:1577468. doi: 10.3389/fonc.2025.1577468 View source version on Contacts Investor Contact Investor Relationsir@ +1-972-277-1136
Irish Times
10-07-2025
- Health
- Irish Times
Biomaterials and ‘brains in a dish' for future treatments
What is your line of work? All of my research is about the brain. I have two main lines of research in my lab. In one, we are developing ways to test how mechanical forces and drugs affect brain cells. We grow the brain cells in the lab and see how they behave under various conditions. The other is research on an approach we call TrapKill, which uses a biomaterial that we are engineering with the hope to make therapies for brain cancer more effective. My work applies engineering in medicine, and I have a joint appointment in the medicine and engineering schools here at the University of Galway and I work in Cúram, which is the Research Ireland Centre for Medical Devices. TrapKill is a dramatic name – tell us more about it TrapKill is a type of material called a hydrogel, which can be put into the body. We make it with three-dimensional channels in it that are designed to trap and compress cells. READ MORE The ultimate idea is that after a brain tumour, such as glioblastoma, is removed by surgery, the gel could be placed in the cavity to weaken the trapped cancer cells and make them more susceptible to radiation and drug treatments. I got funding for this project from the European Research Council. You also grow 'brains in a dish' – can you explain? We programme commercially available stem cells to grow into brains from the cortical region, particularly. Still, we can also combine them with other brain regions. I got national funding for this project through Research Ireland and Cúram. What do you do with these groups of brain cells? For some of them, we look at what happens when force is applied to them. This helps us to better understand how cells could respond to traumatic brain injury. We also look at how the groups of cells respond to each other. For example, if we combine cells from different brain regions, we see faster development of star-shaped cells called astrocytes that carry out many functions in the brain. How did you become interested in research? Growing up in Medellín, Colombia, my parents were a huge inspiration. My father is a pharmaceutical chemist, and my mother is a retired bacteriologist. I loved visiting their labs as a child, and they inspired in me the persistence and rigour that are important for research. They still inspire me. What was your journey to Galway? I studied in Colombia, the United States, Italy and France, and I completed my PhD with Dr Manus Biggs in Galway. I then worked in the UK for a few years before returning to Cúram in 2022 and establishing my own lab here. What keeps you going in your research? I really love it. It's hard work, the hours are long and you are always thinking about it, but I have a huge passion for research. I see so many people now who are living with cancer and brain diseases, and these are areas where we need research for even better treatments. This keeps me going. What do you like to do outside of research? I do reformer Pilates religiously, which keeps me strong and flexible. It's a great antidote to all the sitting down and writing I do as part of my research. I love walking around and painting. I also have lovely plants that I take care of.
Yahoo
09-07-2025
- Business
- Yahoo
4BIO Capital co-leads Actithera's oversubscribed $75.5 million Series A financing
4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, with syndicate including Bioqube Ventures, Surveyor Capital (a Citadel company) and others Proceeds will support clinical development of Actithera's fibroblast activation protein (FAP)-targeting candidate and pipeline expansion London, United Kingdom, 9 July 2025 – 4BIO Capital ('4BIO' or 'the Group'), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that it has co-led a $75.5 million Series A Financing round of Actithera (the 'Company'). Radiopharmaceutical therapy (or radioligand therapy, RLT) is a targeted form of radiotherapy that can treat cancers resistant to other therapies and represents a $7.5 billion market projected to grow to $14.4 billion by 20341. RLTs with the appropriate pharmacokinetic profile can achieve efficacy with minimal toxicity; however, attaining the ideal pharmacokinetic characteristics is not trivial. 4BIO's investment in Actithera highlights the clear need for a more systematic approach to optimizing RLT vectors and exemplifies the Group's strategy of identifying critical technology gaps, backing innovative solutions, and supporting them in high-growth markets. 4BIO co-led the oversubscribed round alongside founding investor M Ventures, Hadean Ventures, and Sofinnova Partners with additional participation from Bioqube Ventures, Innovestor's Life Science Fund, Investinor, Surveyor Capital (a Citadel company), and the second founding investor, Arkin Bio Ventures II. Therese Liechtenstein, incoming Board Member and Investment Director at 4BIO Capital, said: 'At 4BIO we invest in companies solving technical unmet needs to enable next-generation therapeutics. We are honoured to support Actithera, whose pipeline of molecules addresses key challenges in the nascent radioligand therapies space; a large therapeutic window through high tumour retention and low systemic exposure, applied to a lead programme that has significant pan-tumour therapeutic potential.' Dr Andreas Goutopoulous, Founder and CEO of Actithera, added: 'We are grateful for 4BIO Capital's support in this oversubscribed Series A, which is a strong validation of our approach. We set out to bring structure-based and kinetics-driven thinking from small molecule drug design into the world of radiopharmaceuticals. We engineer our radioconjugates for extended retention within tumours, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients.' As part of the Series A financing, Therese Liechtenstein, Investment Director at 4BIO Capital will join the Actithera Board of Directors. The financing will support the advancement of Actithera's lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline. The Company's discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Its three-pillar platform includes first-in-class covalent targeting strategies, designed to optimize tumour residence time, while ensuring rapid systemic clearance – improving precision, safety, and efficacy. Two additional proprietary approaches further support compound differentiation and improve tumour residence time and selectivity. This platform was validated through Actithera's work on FAP, a high-value theranostic target known for being difficult to drug with molecules that maintain prolonged tumour residency. These efforts have resulted in a FAP-directed RLT development candidate with best-in-class potential due to its optimal pharmacokinetic profile and tumour specificity. Dr Andreas Goutopoulos, founder and CEO, brings over 25 years of pharmaceutical and biotech industry experience, including a track record of more than a dozen development candidates. His background includes over a decade of discovery leadership at EMD Serono, where he led medicinal chemistry. In his role as Entrepreneur-in-Residence (EIR) at M Ventures, he led the scientific efforts of and supported a number of oncology small molecule biotechs. At Actithera, he is pioneering a chemistry-driven, precision approach to RLTs by integrating novel covalent-targeting chemistries, rational drug design principles and an isotope-agnostic philosophy. - End - Contacts 4BIO Capital +44 (0) 203 427 5500info@ ICR HealthcareAmber Fennell, Jonathan Edwards, Kris Lam +44 (0)20 3709 57004biocapital@ About 4BIO Capital4BIO Capital ('4BIO') is an international venture capital firm focused on investing in advanced therapies and emerging modalities, to unlock the treatments of the future. 4BIO's mission is to invest in, support, and grow early-stage companies solving technical bottlenecks that enable next generation therapeutics in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially transformative therapies for all patients. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors with an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, connect with us on LinkedIn and Twitter @4biocapital and visit About ActitheraActithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio-Holdings, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology. Learn more at and on LinkedIn. 1 in to access your portfolio
Yahoo
09-07-2025
- Business
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
